
Fragment 176-191 of growth hormone — preserves GH's lipolytic action without its effects on IGF-1 or glucose.
Ranges cited in research literature. Not a usage recommendation. For research use only.
AOD-9604 is a synthetic fragment of human growth hormone: amino acids 176 to 191 of the C-terminal end, with a tyrosine added at the N-terminus for stability. It was developed at Monash University (Australia) by Frank Ng's group and licensed to Metabolic Pharmaceuticals in the late 1990s. The design idea was to isolate the region of GH associated with lipid metabolism while leaving out the part responsible for growth and IGF-1 elevation.
In obese rodent models the fragment stimulated lipolysis and reduced lipogenesis without activating the GH receptor or altering glucose or IGF-1, which sets it apart from the full hormone. The proposed mechanism involves β3-adrenergic signaling in the adipocyte, although it was never fully characterized. The molecule carries a disulfide bridge between cysteines 182 and 189 that holds its conformation; without it, activity in in-vitro assays drops.
The clinical program was large for a peptide of this kind: several hundred participants in oral Phase 2 trials. In 2007 the Phase 2b obesity trial missed its primary endpoint and drug development stopped, although tolerability was good across studies. Since then AOD-9604 has existed as a research compound; laboratory convention uses the subcutaneous route, unlike the oral route of the trials, a nuance that matters when reading the literature. Renova's material is strictly for research use.
| Class | Modified C-terminal fragment of hGH (hGH 176-191) |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa) · disulfide Cys182–Cys189 |
| CAS | 221231-10-3 |
| Origin | Monash University / Metabolic Pharmaceuticals (Australia) |
| Regulatory status | Oral Phase 2b obesity trial missed its primary endpoint in 2007; never approved as a drug |
| Difference from GH | Does not activate the GH receptor; no effect on IGF-1 or glucose in studies |
No. It is a 16-amino-acid fragment matching the tail end of GH (positions 176-191). In studies it does not activate the GH receptor, does not raise IGF-1 and does not affect glucose; it retains only the region associated with lipid metabolism.
Metabolic Pharmaceuticals took the compound to oral Phase 2b in obesity. In 2007 the trial missed its primary efficacy endpoint and pharmaceutical development stopped. Tolerability was good, which is why it remains a compound of research interest.
The cysteines at positions 182 and 189 form a bond that closes a loop and maintains the fragment's three-dimensional shape, as in native GH. It matters for stability: reducing that bridge inactivates the molecule in laboratory assays.
It shares a research area with MOTS-c and 5-Amino-1MQ (energy and lipid metabolism) but through a different mechanism: it is the only direct GH derivative. Our 2026 fat-loss peptide guide compares them in the context of existing trials.
Related reading: AOD-9604: hGH Fragment for Lipolysis · Fat Loss: Complete Peptide Guide (2026)
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty